NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/24/2026 15:54
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization342.9 mln
Float49.21 mln
Earnings Date11/05/2026
Piotroski F-Score
3
/ 9
Below average
1-Year Forecast
17.57
Transformational upside
Relative Strength
93
/ 100
Top performer
Debt / Equity
0.02
Debt-free
ROE
-32.82
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Immuneering Corporation is a Cambridge, Massachusetts-based drug development company focused on creating cancer treatments for large groups of patients. Its lead drug candidate, atebimetinib, is currently in a Phase 3 trial targeting cancers driven by RAS or RAF gene mutations, including pancreatic and lung cancer, and is also being studied in combination with drugs from Regeneron and Eli Lilly. The company has additional drug candidates in earlier stages of testing, along with several ongoing research programs aimed at discovering new treatments.
